drugset / Trial / NCT03341143

Fecal Microbiota Transplant (FMT) in Melanoma Patients

NCT03341143 ↗

NaSingle-groupOpen-labelTreatment

Summary

The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.

Timeline

Start
2018-03-19
Primary completion
2023-09-30
Completion
2024-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications